<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<HTML>
<HEAD>
	<META HTTP-EQUIV="CONTENT-TYPE" CONTENT="text/html; charset=utf-8">
	<TITLE>COMPARATIVE STUDY OF TWO TYPES OF PACEMAKER PROGRAMMING FOR THE TREATAMENT OF UNEXPLAINED SYNCOPE (VASOVAGAL SYNDROME)</TITLE>
	<META NAME="GENERATOR" CONTENT="OpenOffice.org 3.1  (Unix)">
	<META NAME="AUTHOR" CONTENT="mcgill">
	<META NAME="CREATED" CONTENT="20050625;10300000">
	<META NAME="CHANGEDBY" CONTENT="Timothy Church">
	<META NAME="CHANGED" CONTENT="20050625;10300000">
	<META NAME="Info 1" CONTENT="">
	<META NAME="Info 2" CONTENT="">
	<META NAME="Info 3" CONTENT="">
	<META NAME="Info 4" CONTENT="">
	<STYLE TYPE="text/css">
	<!--
		@page { size: 8.27in 11.69in; margin-right: 0.98in; margin-top: 0.5in; margin-bottom: 0.3in }
		@page:first { margin-top: 0.5in; margin-bottom: 0.79in }
		P { margin-bottom: 0in; direction: ltr; color: #000000; text-align: justify; widows: 2; orphans: 2 }
		P.western { font-family: "Times New Roman", serif; font-size: 10pt; so-language: fr-FR; font-style: italic }
		P.cjk { font-family: "Times New Roman", serif; font-size: 10pt; font-style: italic }
		P.ctl { font-family: "Times New Roman", serif; font-size: 10pt; so-language: ar-SA }
		H2 { margin-left: 0.49in; text-indent: -0.49in; margin-top: 0in; margin-bottom: 0in; direction: ltr; color: #000000; widows: 2; orphans: 2 }
		H2.western { font-family: "Helvetica", sans-serif; font-size: 10pt; so-language: en-GB }
		H2.cjk { font-family: "Times New Roman", serif; font-size: 10pt }
		H2.ctl { font-family: "Times New Roman", serif; font-size: 10pt; so-language: ar-SA; font-weight: normal }
		H3 { margin-top: 0in; margin-bottom: 0in; direction: ltr; color: #000000; widows: 2; orphans: 2 }
		H3.western { font-family: "Helvetica", sans-serif; font-size: 10pt; so-language: en-GB }
		H3.cjk { font-family: "Times New Roman", serif; font-size: 10pt }
		H3.ctl { font-family: "Times New Roman", serif; font-size: 10pt; so-language: ar-SA; font-weight: normal }
		H4 { margin-top: 0in; margin-bottom: 0in; direction: ltr; color: #000000; text-align: center; widows: 2; orphans: 2 }
		H4.western { font-family: "Helvetica", sans-serif; font-size: 10pt; so-language: en-GB; font-style: italic }
		H4.cjk { font-family: "Times New Roman", serif; font-size: 10pt; font-style: italic }
		H4.ctl { font-family: "Times New Roman", serif; font-size: 10pt; so-language: ar-SA; font-weight: normal }
		H5 { margin-top: 0in; margin-bottom: 0in; direction: ltr; color: #000000; text-align: center; widows: 2; orphans: 2 }
		H5.western { font-family: "Helvetica", sans-serif; font-size: 12pt; so-language: en-GB }
		H5.cjk { font-family: "Times New Roman", serif; font-size: 12pt }
		H5.ctl { font-family: "Times New Roman", serif; so-language: ar-SA; font-weight: normal }
		H6 { margin-right: -0.2in; margin-top: 0in; margin-bottom: 0in; direction: ltr; color: #000000; text-align: center; widows: 2; orphans: 2; text-decoration: underline }
		H6.western { font-family: "Helvetica", sans-serif; font-size: 10pt; so-language: en-GB }
		H6.cjk { font-family: "Times New Roman", serif; font-size: 10pt }
		H6.ctl { font-family: "Times New Roman", serif; font-size: 10pt; so-language: ar-SA; font-weight: normal }
		P.sdfootnote-western { color: #000000; font-family: "Times New Roman", serif; font-size: 10pt; so-language: fr-FR; text-align: left }
		P.sdfootnote-cjk { color: #000000; font-family: "Times New Roman", serif; font-size: 10pt; text-align: left }
		P.sdfootnote-ctl { color: #000000; font-family: "Times New Roman", serif; font-size: 10pt; so-language: ar-SA; text-align: left }
	-->
	</STYLE>
</HEAD>
<BODY LANG="en-US" TEXT="#000000" DIR="LTR">
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=CENTER STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><FONT SIZE=4><B>COMPARATIVE STUDY
OF TWO TYPES OF PACING FOR THE TREATMENT OF UNEXPLAINED SYNCOPE
(VASOVAGAL SYNDROME)</B></FONT></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">SPONSOR:				Medtronic France</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">					122 av. du Général Leclerc</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">					92514 Boulogne-Billancourt
Cedex</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-left: 1.97in; margin-right: -0.2in; text-indent: 0.49in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">France</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">					Tel.:	(+33) -1 55 38 17 00</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">					Fax:	(+33) -1 55 38 18 00</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">PROJECT MANAGER			Cécile  Laiter
de Monclin, M.D.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-left: 1.97in; margin-right: -0.2in; text-indent: 0.49in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">Medtronic France</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">					122 av. du Général Leclerc</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">					92514 Boulogne-Billancourt
Cedex</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-left: 1.97in; margin-right: -0.2in; text-indent: 0.49in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">France</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">					Tel.:	(+33) -1 55 38 17 43</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">					Fax:	(+33) -1 55 38 17 83</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">PRINCIPAL INVESTIGATOR:		Daniel
</FONT><FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif">Flammang,
M.D.</FONT></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">					Department of Cardiology </FONT>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">					Hôpital d'Angoulême</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">					16470 Saint Michel</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-left: 1.97in; margin-right: -0.2in; text-indent: 0.49in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">France</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">					Tel.:	(+33) –5 45 24 41 07</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">					Fax:	(+33) –5 45 24 41 05</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in">
<FONT FACE="Helvetica, sans-serif"><I><B>CONFIDENTIALITY AGREEMENT</B></I></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="font-style: normal">
<FONT FACE="Helvetica, sans-serif">The confidential information
contained in the present document is provided for your information to
you as investigator, to your team and to the Consultative Committee
for the Protection of Persons in Biomedical Research</FONT><FONT FACE="Helvetica, sans-serif"><I>
(Comité Consultatif pour la Protection des Personnes dans la
Recherche Biomédicale</I></FONT><FONT FACE="Helvetica, sans-serif">)
(C.C.P.P.R.B). By accepting the document you undertake not to divulge
said information to any third party without the sponsor’s written
permission. You may, however, give the information to patients in
order to obtain their consent.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="font-style: normal; page-break-before: always">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><U><B>1 – SUMMARY OF STUDY</B></U></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><B>Objective of the study: </B></FONT><FONT FACE="Helvetica, sans-serif">To
compare the effectiveness of a dual chamber pacing (DDD)  at 70 bpm
and a single chamber atrial pacing (AAI)  at 30 bpm in patients
suffering from vasovagal syndrome related to a predominant
cardio-inhibitory reflex determined by ATP test.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><B>Assessment criteria: </B></FONT><FONT FACE="Helvetica, sans-serif">Onset
and onset interval of recurrence of first vagal symptom of intensity
at least as great as that of the spontaneous symptoms, following
pacemaker implantation.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif"><B>Treatments
compared: </B></FONT></FONT><FONT FACE="Helvetica, sans-serif">Dual
chamber pacing at 70 bpm and a single chamber atrial pacing at 30
bpm.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT COLOR="#000000"> </FONT><FONT FACE="Helvetica, sans-serif"><B>Programming:	</B></FONT><FONT FACE="Helvetica, sans-serif">Group
A: AAI mode - 30 bpm</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif">			Group B:
DDD </FONT></FONT><FONT FACE="Helvetica, sans-serif">mode </FONT><FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif">-
70 bpm </FONT></FONT>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-left: 1.47in; margin-right: -0.2in; text-indent: -1.47in; font-style: normal">
<FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif"><B>Type of
study:</B></FONT></FONT><FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif">	Prospective
multicentre comparative randomised single-blind study, with a direct
individual benefit.</FONT></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif"><B>Number of
patients: </B></FONT></FONT><FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif">200
patients (100 per group), positive on ATP test.</FONT></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><B>Study population:</B></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><B>1. </B></FONT><FONT FACE="Helvetica, sans-serif"><U><B>Inclusion
criteria</B></U></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif">- Adult
patients</FONT></FONT><FONT FACE="Helvetica, sans-serif"> (</FONT><FONT FACE="Symbol, serif"></FONT><FONT FACE="Helvetica, sans-serif">
18 yrs), agreeing to take part in the study and having signed the
informed consent form</FONT><FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif">.</FONT></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">- Patients having presented one or
more episodes of syncope or pre-syncope unexplained by the usual
screening tests: questionnaire, clinical examination, orthostatic
hypotension investigation, biological tests, electrophysiological
study (if necessary), echocardiogram, ECG, Holter, exercise test
(optional), EEG (optional), and brain scan (optional). </FONT>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><U>- Negative sino-carotid massage
(SCM) (Appendix A).</U></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">- Head-up tilt test conducted
according to Appendix B protocol, whatever the result.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif">- Positive
a</FONT></FONT><FONT FACE="Helvetica, sans-serif">denosine-5'-triphospate
</FONT><FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif">(ATP)
test (Appendix C), confirmed by double reading by principal
investigator. </FONT></FONT>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><B>2. </B></FONT><FONT FACE="Helvetica, sans-serif"><U><B>Exclusion
criteria</B></U></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">- Syncope etiology revealed by
usual sc reening testings.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">- Positive SCM (Appendix A).</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">- Atrial or ventricular
tachyarrhythmia.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">- Defibrillator implanted (DAI).</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">- Pacemaker previously implanted.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">- Patient on waiting list for or
having had heart transplantation.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">- Sick sinus syndrome, brady-tachy
syndrome.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">- Atrial fibrillation, paroxysmal
or permanent first and second-degree atrio-ventricular block,
trifascicular block.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">- Ongoing pregnancy. Women of
childbearing age should be using reliable contraception</FONT><FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif">.</FONT></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">- Acute systemic infection or
other surgical contra-indication for pacemaker implantation.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">- Chronic obstructive
bronchopneumopathy.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">- Asthma.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">- Diabetes.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif"><B>Randomisation:
</B></FONT></FONT><FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif">Rate
and mode of cardiac stimulation (single blind study)</FONT></FONT><FONT FACE="Helvetica, sans-serif">.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif"><B>Follow-up
protocol: - </B></FONT></FONT><FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif">The
first recurrence of a vagal symptom (at least as severe as
spontaneous symptoms) must be checked in outpatient clinics; the
patient will be systematically removes from the study.</FONT></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-left: 0.98in; margin-right: -0.2in; text-indent: 0.49in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">- Besides this first recurrence,
the pacemaker functioning will be checked as usual </FONT>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">at 2, 6, 12, 18 and 24 months in
out patient clinics </FONT>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><B>Planned schedule: 	</B></FONT><FONT FACE="Helvetica, sans-serif">Beginning
of inclusions: 	January 2000</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">		   	End of inclusions:		December
2002</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">			Final FU (at 2 yrs):		December
2004</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=CENTER STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=CENTER STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><FONT SIZE=4><U><B>Investigation
centres:</B></U></FONT></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=CENTER STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><B>Centre N°1			</B></FONT><FONT FACE="Helvetica, sans-serif">C.H.G.
d'Angoulême, Hôpital de Girac</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">Dr. Daniel Flammang		Route de
Bordeaux</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><I>Principal investigator</I></FONT><FONT FACE="Helvetica, sans-serif">		16470
Saint Michel</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">				France</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-left: 0.98in; margin-right: -0.2in; text-indent: 0.49in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">	Tel: (+33) -5 45 24 41 07</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">				Fax:(+33) -5 </FONT><FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif">45
24 41 05</FONT></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><B>Centre N°2</B></FONT><FONT FACE="Helvetica, sans-serif">			C.H.U.
Angers</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">Dr.Jacques Victor		4, rue Larrey</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">				49033 Angers Cedex 1</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-left: 1.48in; margin-right: -0.2in; text-indent: 0.49in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">France</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">				Tel: (+33) -2 41 35 48 58</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">				Fax:(+33) -2 41 35 40 05</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">				</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><B>Centre N° 3</B></FONT><FONT FACE="Helvetica, sans-serif">
			C.H.R.U. Brest, Hôpital de la Cavale Blanche</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">Pr. Jean-Jacques Blanc		5, avenue
Foch</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">				29609 Brest Cedex</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-left: 1.48in; margin-right: -0.2in; text-indent: 0.49in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">France</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">				Tel: (+33) -2 98 34 73 91</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">				Fax:(+33) -2 98 34 73 93</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">				</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><B>Centre  N° 4</B></FONT><FONT FACE="Helvetica, sans-serif">
			Cliniques Universitaires de Mont-Godinne</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="font-style: normal">
<FONT FACE="Helvetica, sans-serif">Pr. Luc de Roy			</FONT><FONT FACE="Helvetica, sans-serif">1
rue Dr Therasse</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-left: 1.48in; text-indent: 0.49in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">5530 Yvoir</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-left: 1.48in; text-indent: 0.49in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">Belgium</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
				<FONT FACE="Helvetica, sans-serif">Tel: (+32) 81 42 36 01</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-left: 1.48in; text-indent: 0.49in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">Fax:(+32) 81 42 36 03</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-left: 1.48in; text-indent: 0.49in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><B>Centre N° 5</B></FONT><FONT FACE="Helvetica, sans-serif">
			C.H.R.U. Hôpital Sud</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">Pr. Jean Luc REY		Rue Laënnec</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">				80054 Amiens Cedex 1</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">				France</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">				Tel: (+33) -3.22.45.60.00</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">				Fax:(+33) -3.22.45.57.98</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">				</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><B>Centre N° 6			</B></FONT><FONT FACE="Helvetica, sans-serif">C.H.
Saint Philibert</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">Dr. Pierre Graux		115 Rue du Grand
But</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">				59462 Lomme Cedex</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">				France</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">				Tel: (+33) -3.20.22.50.53</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">				Fax:(+33) -3.20.22.50.58</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-left: 1.48in; text-indent: 0.49in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
 <FONT FACE="Helvetica, sans-serif"><B>Centre N° 7</B></FONT><FONT FACE="Helvetica, sans-serif">
			Hôpital Jean Rostand</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">Dr. Robert Frank		39 rue le Galleu
</FONT>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-left: 1.48in; margin-right: -0.2in; text-indent: 0.49in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">94205 Ivry sur Seine</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-left: 1.48in; margin-right: -0.2in; text-indent: 0.49in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">France</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">				Tel: (+33) 1 49 59 70 65</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">				Fax:(+33) 1 49 59 70 73</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-left: 1.48in; margin-right: -0.2in; text-indent: 0.49in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><B>Centre N°8			</B></FONT><FONT FACE="Helvetica, sans-serif">Hôpital
d’Instruction des Armées</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">Dr. Roland Carlioz		101, Avenue
Henry Barbusse, BP 406</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">				91141 Clamart Cedex</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">				France</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">				Tel: (+33) 1 41 46 62 40</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">				Fax:(+33) 1 41 46 64 49</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><B>Centre N° 9</B></FONT><FONT FACE="Helvetica, sans-serif">
			Royal Brompton Hospital</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">Dr. Richard Sutton		Sidney Street </FONT>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-left: 1.48in; margin-right: -0.2in; text-indent: 0.49in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">London SW3 6NP</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-left: 1.48in; margin-right: -0.2in; text-indent: 0.49in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">United Kingdom</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">				Tel: (+44) 207 352 8121</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">				Fax:(+44) </FONT>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-left: 1.48in; margin-right: -0.2in; text-indent: 0.49in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><B>Centre N°10			</B></FONT><FONT FACE="Helvetica, sans-serif">Royal
Victoria Hospital</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">Pr. Rosanne Kenny		Queen Victoria
Road</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">				Newcastle upon Tyne  NE1 4LP</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">				United Kingdom</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">				Tel: (+44) 191 232 5131</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">				Fax:(+44) </FONT>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=CENTER STYLE="margin-right: -0.2in; font-style: normal; page-break-before: always">
<BR>
</P>
<P LANG="" CLASS="western" ALIGN=CENTER STYLE="margin-right: -0.2in"><SPAN ID="Frame3" DIR="LTR" STYLE="float: left; width: 1.15in; height: 0.32in; border: 1.00pt solid #000000; padding: 0.06in 0.11in; background: #ffffff">
	<H4 LANG="en-GB" CLASS="western">Inclusion</H4>
</SPAN>
<SPAN ID="Frame2" DIR="LTR" STYLE="float: left; width: 1.52in; height: 0.32in; border: 1.00pt solid #000000; padding: 0.06in 0.11in; background: #ffffff">
	<P LANG="en-GB" CLASS="western" ALIGN=LEFT><FONT FACE="Helvetica, sans-serif"><I><B>Clinical
	phase</B></I></FONT></P>
	<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="font-style: normal">
	<BR>
	</P>
</SPAN>
<SPAN ID="Frame1" DIR="LTR" STYLE="float: left; width: 2.31in; height: 0.44in; border: 1.00pt solid #000000; padding: 0.07in 0.12in; background: #ffffff">
	<H5 LANG="en-GB" CLASS="western">STUDY FLOWCHART</H5>
</SPAN><BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT><BR>
</P>
<P LANG="" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<IMG SRC="en_protocol-2002-02-21_html_3eb3fdcf.gif" ALIGN=LEFT HSPACE=12><IMG SRC="en_protocol-2002-02-21_html_m7b155fe5.gif" ALIGN=LEFT HSPACE=12><IMG SRC="en_protocol-2002-02-21_html_21f56f91.gif" ALIGN=LEFT HSPACE=12><BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<SPAN ID="Frame4" DIR="LTR" STYLE="float: left; width: 2.45in; height: 0.34in; border: 1.00pt solid #000000; padding: 0.06in 0.11in; background: #ffffff">
	<H3 LANG="en-GB" CLASS="western">Positive SCM<FONT FACE="Wingdings"></FONT>
	Exclusion</H3>
</SPAN>
<IMG SRC="en_protocol-2002-02-21_html_2a044fc9.gif" ALIGN=LEFT HSPACE=12><BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-left: 0.49in; text-indent: -0.49in; font-style: normal">
<BR>
</P>
<P LANG="" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<IMG SRC="en_protocol-2002-02-21_html_2a044fc9.gif" ALIGN=LEFT HSPACE=12><SPAN ID="Frame5" DIR="LTR" STYLE="float: left; width: 2.44in; height: 0.32in; border: 1.00pt solid #000000; padding: 0.06in 0.11in; background: #ffffff">
	<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="font-style: normal">
	<FONT FACE="Helvetica, sans-serif"><SPAN LANG=""><B>Negative ATP
	test </B></SPAN></FONT><FONT FACE="Wingdings"><B></B></FONT><FONT FACE="Helvetica, sans-serif"><B>
	Exclusion</B></FONT></P>
</SPAN><BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<SPAN ID="Frame6" DIR="LTR" STYLE="float: left; width: 0.62in; height: 0.32in; border: 1.00pt solid #000000; padding: 0.06in 0.11in; background: #ffffff">
	<P LANG="fr-FR" ALIGN=LEFT STYLE="font-style: normal"><FONT FACE="Helvetica, sans-serif"><FONT SIZE=2><B>TILT</B></FONT></FONT></P>
</SPAN><BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<IMG SRC="en_protocol-2002-02-21_html_7bb5816a.gif" ALIGN=LEFT HSPACE=12><IMG SRC="en_protocol-2002-02-21_html_m743de89d.gif" ALIGN=LEFT HSPACE=12><IMG SRC="en_protocol-2002-02-21_html_670c7611.gif" ALIGN=LEFT HSPACE=12><SPAN ID="Frame8" DIR="LTR" STYLE="float: left; width: 0.62in; height: 0.32in; border: 1.00pt solid #000000; padding: 0.06in 0.11in; background: #ffffff">
	<H2 LANG="en-GB" CLASS="western">ATP</H2>
</SPAN>
<SPAN ID="Frame7" DIR="LTR" STYLE="float: left; width: 0.62in; height: 0.32in; border: 1.00pt solid #000000; padding: 0.06in 0.11in; background: #ffffff">
	<H2 LANG="en-GB" CLASS="western">SCM</H2>
</SPAN>
<IMG SRC="en_protocol-2002-02-21_html_5988b9c2.gif" ALIGN=LEFT HSPACE=12>
<IMG SRC="en_protocol-2002-02-21_html_m266d659a.gif" ALIGN=LEFT HSPACE=12>
<IMG SRC="en_protocol-2002-02-21_html_dc9eea4.gif" ALIGN=LEFT HSPACE=12>
<IMG SRC="en_protocol-2002-02-21_html_m266d659a.gif" ALIGN=LEFT HSPACE=12>
<IMG SRC="en_protocol-2002-02-21_html_60266e84.gif" ALIGN=LEFT HSPACE=12>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<SPAN ID="Frame9" DIR="LTR" STYLE="float: left; width: 3.32in; height: 0.32in; border: 1.00pt solid #000000; padding: 0.06in 0.11in; background: #ffffff">
	<P LANG="en-GB" CLASS="western" ALIGN=CENTER STYLE="font-style: normal">
	<FONT FACE="Helvetica, sans-serif"><SPAN LANG=""><B>Positive ATP
	test </B></SPAN></FONT><FONT FACE="Wingdings"><B></B></FONT><FONT FACE="Helvetica, sans-serif"><B>
	Dual chamber PM implantation</B></FONT></P>
</SPAN><BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<IMG SRC="en_protocol-2002-02-21_html_m3214bbcd.gif" ALIGN=LEFT HSPACE=12><IMG SRC="en_protocol-2002-02-21_html_m3214bbcd.gif" ALIGN=LEFT HSPACE=12><IMG SRC="en_protocol-2002-02-21_html_m3214bbcd.gif" ALIGN=LEFT HSPACE=12><IMG SRC="en_protocol-2002-02-21_html_m3214bbcd.gif" ALIGN=LEFT HSPACE=12><SPAN ID="Frame10" DIR="LTR" STYLE="float: left; width: 1.02in; height: 0.32in; border: 1.00pt solid #000000; padding: 0.06in 0.11in; background: #ffffff">
	<H3 LANG="en-GB" CLASS="western">Group A</H3>
</SPAN><BR>
</P>
<P LANG="" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<IMG SRC="en_protocol-2002-02-21_html_6015067b.gif" ALIGN=LEFT HSPACE=12><IMG SRC="en_protocol-2002-02-21_html_363a11e3.gif" ALIGN=LEFT HSPACE=12><IMG SRC="en_protocol-2002-02-21_html_6c8e9655.gif" ALIGN=LEFT HSPACE=12><IMG SRC="en_protocol-2002-02-21_html_6c8e9655.gif" ALIGN=LEFT HSPACE=12><IMG SRC="en_protocol-2002-02-21_html_6c8e9655.gif" ALIGN=LEFT HSPACE=12><BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<IMG SRC="en_protocol-2002-02-21_html_m44c4bab8.gif" ALIGN=LEFT HSPACE=12><SPAN ID="Frame12" DIR="LTR" STYLE="float: left; width: 1.02in; height: 0.32in; border: 1.00pt solid #000000; padding: 0.06in 0.11in; background: #ffffff">
	<H3 LANG="en-GB" CLASS="western">Group B</H3>
</SPAN>
<SPAN ID="Frame11" DIR="LTR" STYLE="float: left; width: 1.22in; height: 0.46in; border: 1.00pt solid #000000; padding: 0.06in 0.11in; background: #ffffff">
	<P LANG="en-GB" CLASS="western" ALIGN=CENTER STYLE="font-style: normal">
	<FONT FACE="Helvetica, sans-serif"><B>Single-blind randomisation </B></FONT>
	</P>
</SPAN><BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<IMG SRC="en_protocol-2002-02-21_html_363a11e3.gif" ALIGN=LEFT HSPACE=12><BR>
</P>
<P LANG="" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<SPAN ID="Frame13" DIR="LTR" STYLE="float: left; width: 1.52in; height: 0.45in; border: 1.00pt solid #000000; padding: 0.06in 0.11in; background: #ffffff">
	<P LANG="fr-FR" CLASS="sdfootnote-western"><FONT FACE="Helvetica, sans-serif"><B>FU
	at 2, 6,12, 18, 24 months</B></FONT></P>
</SPAN><BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<CENTER>
	<TABLE WIDTH=668 BORDER=1 BORDERCOLOR="#000000" CELLPADDING=5 CELLSPACING=0 RULES=COLS>
		<COL WIDTH=217>
		<COL WIDTH=78>
		<COL WIDTH=74>
		<COL WIDTH=43>
		<COL WIDTH=43>
		<COL WIDTH=49>
		<COL WIDTH=42>
		<COL WIDTH=38>
		<TBODY>
			<TR VALIGN=TOP>
				<TD WIDTH=217 BGCOLOR="#f2f2f2">
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					<BR>
					</P>
				</TD>
				<TD WIDTH=78 BGCOLOR="#f2f2f2">
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					<FONT FACE="Helvetica, sans-serif">Selection </FONT>
					</P>
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					<FONT FACE="Helvetica, sans-serif">phase</FONT></P>
				</TD>
				<TD WIDTH=74 BGCOLOR="#f2f2f2">
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					<FONT FACE="Helvetica, sans-serif">Inclusion</FONT></P>
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					<FONT FACE="Helvetica, sans-serif">M0</FONT></P>
				</TD>
				<TD WIDTH=43 BGCOLOR="#f2f2f2">
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					<FONT FACE="Helvetica, sans-serif">M2</FONT></P>
				</TD>
				<TD WIDTH=43 BGCOLOR="#f2f2f2">
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					<FONT FACE="Helvetica, sans-serif">M6</FONT></P>
				</TD>
				<TD WIDTH=49 BGCOLOR="#f2f2f2">
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					<FONT FACE="Helvetica, sans-serif">M12</FONT></P>
				</TD>
				<TD WIDTH=42 BGCOLOR="#f2f2f2">
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					<FONT FACE="Helvetica, sans-serif">M18</FONT></P>
				</TD>
				<TD WIDTH=38 BGCOLOR="#f2f2f2">
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					<FONT FACE="Helvetica, sans-serif">M24</FONT></P>
				</TD>
			</TR>
		</TBODY>
		<TBODY>
			<TR VALIGN=TOP>
				<TD WIDTH=217 HEIGHT=43 BGCOLOR="#f2f2f2">
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					<FONT FACE="Helvetica, sans-serif">Carotid massage </FONT>
					</P>
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					<FONT FACE="Helvetica, sans-serif">Chest X-ray</FONT></P>
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					<FONT FACE="Helvetica, sans-serif">Exclusion of syncope of known
					origin</FONT></P>
				</TD>
				<TD WIDTH=78>
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					</P>
				</TD>
				<TD WIDTH=74>
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					<BR>
					</P>
				</TD>
				<TD WIDTH=43>
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					<BR>
					</P>
				</TD>
				<TD WIDTH=43>
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					<BR>
					</P>
				</TD>
				<TD WIDTH=49>
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					<BR>
					</P>
				</TD>
				<TD WIDTH=42>
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					<BR>
					</P>
				</TD>
				<TD WIDTH=38>
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					<BR>
					</P>
				</TD>
			</TR>
		</TBODY>
		<TBODY>
			<TR VALIGN=TOP>
				<TD WIDTH=217 BGCOLOR="#f2f2f2">
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					<FONT FACE="Helvetica, sans-serif">ECG</FONT></P>
				</TD>
				<TD WIDTH=78>
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					</P>
				</TD>
				<TD WIDTH=74>
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					<BR>
					</P>
				</TD>
				<TD WIDTH=43>
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					</P>
				</TD>
				<TD WIDTH=43>
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					</P>
				</TD>
				<TD WIDTH=49>
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					</P>
				</TD>
				<TD WIDTH=42>
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					</P>
				</TD>
				<TD WIDTH=38>
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					</P>
				</TD>
			</TR>
		</TBODY>
		<TBODY>
			<TR VALIGN=TOP>
				<TD WIDTH=217 BGCOLOR="#f2f2f2">
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					<FONT FACE="Helvetica, sans-serif">ATP Test followed by Tilt
					Test </FONT>
					</P>
				</TD>
				<TD WIDTH=78>
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					<BR>
					</P>
				</TD>
				<TD WIDTH=74>
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					</P>
				</TD>
				<TD WIDTH=43>
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					<BR>
					</P>
				</TD>
				<TD WIDTH=43>
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					<BR>
					</P>
				</TD>
				<TD WIDTH=49>
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					<BR>
					</P>
				</TD>
				<TD WIDTH=42>
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					<BR>
					</P>
				</TD>
				<TD WIDTH=38>
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					<BR>
					</P>
				</TD>
			</TR>
		</TBODY>
		<TBODY>
			<TR VALIGN=TOP>
				<TD WIDTH=217 BGCOLOR="#f2f2f2">
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					<FONT FACE="Helvetica, sans-serif">Informed consent</FONT></P>
				</TD>
				<TD WIDTH=78>
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					<BR>
					</P>
				</TD>
				<TD WIDTH=74>
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					</P>
				</TD>
				<TD WIDTH=43>
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					<BR>
					</P>
				</TD>
				<TD WIDTH=43>
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					<BR>
					</P>
				</TD>
				<TD WIDTH=49>
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					<BR>
					</P>
				</TD>
				<TD WIDTH=42>
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					<BR>
					</P>
				</TD>
				<TD WIDTH=38>
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					<BR>
					</P>
				</TD>
			</TR>
			<TR VALIGN=TOP>
				<TD WIDTH=217 BGCOLOR="#f2f2f2">
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					<FONT FACE="Helvetica, sans-serif">PM implantation </FONT>
					</P>
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					<FONT FACE="Helvetica, sans-serif">Randomisation programming</FONT></P>
				</TD>
				<TD WIDTH=78>
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					<BR>
					</P>
				</TD>
				<TD WIDTH=74>
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					</P>
				</TD>
				<TD WIDTH=43>
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					<BR>
					</P>
				</TD>
				<TD WIDTH=43>
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					<BR>
					</P>
				</TD>
				<TD WIDTH=49>
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					<BR>
					</P>
				</TD>
				<TD WIDTH=42>
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					<BR>
					</P>
				</TD>
				<TD WIDTH=38>
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					<BR>
					</P>
				</TD>
			</TR>
		</TBODY>
		<TBODY>
			<TR VALIGN=TOP>
				<TD WIDTH=217 BGCOLOR="#f2f2f2">
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					<FONT FACE="Helvetica, sans-serif">Clinical assessment</FONT></P>
				</TD>
				<TD WIDTH=78>
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					</P>
				</TD>
				<TD WIDTH=74>
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					</P>
				</TD>
				<TD WIDTH=43>
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					</P>
				</TD>
				<TD WIDTH=43>
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					</P>
				</TD>
				<TD WIDTH=49>
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					</P>
				</TD>
				<TD WIDTH=42>
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					</P>
				</TD>
				<TD WIDTH=38>
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					</P>
				</TD>
			</TR>
		</TBODY>
		<TBODY>
			<TR VALIGN=TOP>
				<TD WIDTH=217 BGCOLOR="#f2f2f2">
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					<FONT FACE="Helvetica, sans-serif">PM reprogramming (HR)</FONT></P>
				</TD>
				<TD WIDTH=78>
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					<BR>
					</P>
				</TD>
				<TD WIDTH=74>
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					<BR>
					</P>
				</TD>
				<TD WIDTH=43>
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					</P>
				</TD>
				<TD WIDTH=43>
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					</P>
				</TD>
				<TD WIDTH=49>
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					</P>
				</TD>
				<TD WIDTH=42>
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					</P>
				</TD>
				<TD WIDTH=38>
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					</P>
				</TD>
			</TR>
		</TBODY>
		<TBODY>
			<TR VALIGN=TOP>
				<TD WIDTH=217 BGCOLOR="#f2f2f2">
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					<FONT FACE="Helvetica, sans-serif">Adverse events</FONT></P>
				</TD>
				<TD WIDTH=78>
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					<BR>
					</P>
				</TD>
				<TD WIDTH=74>
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					</P>
				</TD>
				<TD WIDTH=43>
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					</P>
				</TD>
				<TD WIDTH=43>
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					</P>
				</TD>
				<TD WIDTH=49>
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					</P>
				</TD>
				<TD WIDTH=42>
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					</P>
				</TD>
				<TD WIDTH=38>
					<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
					</P>
				</TD>
			</TR>
		</TBODY>
	</TABLE>
</CENTER>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=CENTER STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=CENTER STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=CENTER STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=CENTER STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=CENTER STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=CENTER STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=CENTER STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal; page-break-before: always">
<FONT FACE="Helvetica, sans-serif"><U><B>2. INTRODUCTION</B></U></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><B>2.1. STUDY RATIONALE </B></FONT>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">Vasovagal syndrome (VVS), as
described by Sir Lewis</FONT><FONT COLOR="#ff0000"><FONT FACE="Helvetica, sans-serif">
</FONT></FONT><FONT FACE="Helvetica, sans-serif">in 1932, refers to
an intense vasoplegia resulting in a sudden and severe drop in blood
pressure (“vaso”), and to a negative dromotropic and chrontropic
phenomenon represented by a bradycardia of varying severity, ranging
from simple sinus bradycardia to an atrio-ventricular or sino-atrial
blockage (“vagal”). It is generally found that, even for a single
given patient, a number of different factors affect the vasovagal
symptoms, the severity of which may depend upon the underlying
mechanism. Also, despite the complexity and central processing of the
vagal afferents, clinical signs tend to concern a vasodilative reflex
more than a cardio-inhibitory reflex, although the two components may
also be combined (1).</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">The head-up tilt test (TT) is
effective for reproducing the symptoms and so, for confirming the
diagnosis. However, it cannot distinguish the underlying mechanism,
even if a positive test is usually associated to a vasodepressive
phenomenon (2,3).</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">The adenosine-5'-triphospate (ATP)
test has been demonstrated to be interesting in revealing the
cardio-inhibitory origin of VVS (4-6). It consists on a 20mg iv bolus
of ATP (Striadyne</FONT><SUP><FONT FACE="Helvetica, sans-serif">®</FONT></SUP><FONT FACE="Helvetica, sans-serif">,
Wyeth Lab.) designated to provoke a severe cardio-inhibitory vagal
response (see appendix C for the the ATP test description) (7). It
has been demonstrated that this test is able to identify those
vasovagal patients with the highest risk of heart sensitivity to the
vagal tone, as indicated by a cardiac pause longer than 10 seconds
(positive test).</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">Therapeutically, 1) for the
vasovagal symptoms refering to a severe drop in blood pressure
(positive TT), no treatment or various drug regimen have been tried
out with varying success. Of these, beta-blockers have proved
effective in 50% of cases, and mainly when the TT is positive under
beta stimulation (isuprel</FONT><SUP><FONT FACE="Helvetica, sans-serif">®</FONT></SUP><FONT FACE="Helvetica, sans-serif">).
Other drugs are also effective: etaphylline, serotonine re-uptake
inhibitors, midodrine, etc..</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">2) When the TT fails to reproduce
the symptoms (negative test) and when there is significant cardiac
pause under ATP (appendix C), the most effective treatment consists
on implanting a permanent pacemaker (4). </FONT>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><B>2.2. VASOVAGAL SYNDROME
EVOLUTIONARY HYPOTHESIS</B></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">A preliminary study found a
significant correlation between patients’ age and ATP test result,
while no such relation was found for the TT (8). These findings
suggest that the vaso-depressive form of VVS is not age-linked,
whereas the cardio-inhibitory form predominates with aging. This may
lead to the following evolutionary hypothesis: VVS may be due to a
simple ortho-parasympathetic balance instability in youth,
deteriorating with age to result in autonomic nervous system
hypersensitivity to any vagal influx. Thus an initial inotropic and
vascular disregulation may give way to chrontropic and dromotropic
disregulation. In this case, the TT may be more effective during the
first phase for detecting the vasoplegic forms predominating at that
time, whereas the ATP test would become more appropriate as the
patient ages for screening for an abnormal cardio-inhibitory reflex
of vagal origin.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><U><B>3 – STUDY OBJECTIVES</B></U></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><B>Main objective:</B></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">The study seeks to compare the
effectiveness of dual chamber 70 bpm pacing in preventing syncope
recurrence as compared to absence of pacing in patients suffering
from VVS related to a predominant cardio-inhibitory reflex as shown
by positive ATP test. Absence of stimulation is simulated by a
temporary pacing (i.e. until the first symptom recurrence) at 30 bpm
single atrial pacing mode (AAI). </FONT>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">The multicentre design of the
study will enlarge the scale reproduction of the generally positive
results published to date. The investigation centers have been chosen
for their clearly manifest interest and great experience in the
treatment of this kind of pathology, guaranteeing the success of the
project.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><B>Secondary objectives:</B></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<UL>
	<LI><P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
	<FONT FACE="Helvetica, sans-serif">To assess the impact of the
	following factors on head-up tilt test and ATP test results:</FONT></P>
</UL>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">	- age,</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">	- sex,</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">	- anatomic parameters
(cardio-thoracic ratio: CTR),</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">	- heart disease and
cardiovascular risk factors.</FONT></P>
<UL>
	<LI><P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
	<FONT FACE="Helvetica, sans-serif">To determine to what extent
	positive or negative tilt test results relate to syncope recurrence
	rates in positive ATP-test patients implanted with pacemakers
	programmed at two possible settings.</FONT></P>
</UL>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><U><B>4 – PATIENT SELECTION</B></U></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><B>4.1. INCLUSION CRITERIA</B></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif">- Adult
patients</FONT></FONT><FONT FACE="Helvetica, sans-serif"> (</FONT><FONT FACE="Symbol, serif"></FONT><FONT FACE="Helvetica, sans-serif">
18 yrs), agreeing to take part in the study and having signed the
informed consent form</FONT><FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif">.</FONT></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">- Patients having presented one or
more episodes of syncope or pre-syncope unexplained by the usual
screening testings: questionnaire, physical examination, orthostatic
hypotension investigation, biological tests, electrophysiological
study (if necessary), echocardiogram, ECG, Holter, exercise test
(optional), EEG (optional), and head CT scan (optional). </FONT>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif">- </FONT></FONT><FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif"><U>Negative
sino-carotid massage (SCM).</U></FONT></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif">- Positive
a</FONT></FONT><FONT FACE="Helvetica, sans-serif">denosine-5'-triphospate
</FONT><FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif">(ATP)
test, confirmed by double reading by principal investigator. (ATP
test must be performed 15 min before tilt test.) </FONT></FONT>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif">- Tilt test
conducted as per Appendix B.</FONT></FONT><FONT FACE="Helvetica, sans-serif">
</FONT>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><B>4.2. NON-INCLUSION CRITERIA</B></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">- Syncope etiology revealed by
usual screening testings.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">- Positive SCM.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">- Atrial or ventricular
tachyarrhythmia.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">- Defibrillator implanted (DAI).</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">- Pacemaker previously implanted.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">- Patient on waiting list for or
having had heart transplantation.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">- Sick sinus syndrome, brady-tachy
syndrome.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">- Atrial fibrillation, paroxysmal
or permanent first and second-degree atrio-ventricular block,
trifascicular block.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">- Ongoing pregnancy. Women of
childbearing age should be using reliable contraception</FONT><FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif">.</FONT></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">- Acute systemic infection or
other surgical contra-indication for pacemaker implantation.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">- Chronic obstructive
bronchopneumopathy.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">- Asthma.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">- Diabetes.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><U><B>5 – STUDY PROCEDURES</B></U></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><B>5.1.  PRACTICAL PROCEDURES</B></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="font-style: normal">
<FONT FACE="Helvetica, sans-serif">Before including a patient in the
study, carotid sinus hypersensitivity or any other obvious syncope
etiology are to be excluded. There is nothing specified as to the
time between SCM and inclusion.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><B>5.1.1. INCLUSION CONSULTATION</B></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">- Investigator review of patient’s
inclusion/exclusion criteria.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">- Obtaining patient’s informed
consent.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">- For each ATP test, a photocopy
of the ECG shall be sent for double reading to the Principle
Investigator. The patient will be randomised only after confirmation
of the positive ATP test result has been received.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><B>So, the ATP test is the
practical means for selecting patients who may be included.</B></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">- Random allocation to one of the
two treatment groups if the patient accepts to be implanted.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="font-style: normal">
<FONT FACE="Helvetica, sans-serif"><B>5.1.2. RANDOMISATION: PACING
RATE AND MODE SETTING (SINGLE-BLIND RANDOMISATION)</B></FONT></P>
<P LANG="en-GB" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">All positive ATP patients will be
implanted with a dual-chamber pacemaker. PM setting will be
randomised prior to implantation. The patients will be divided into 2
groups: </FONT>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><B>Group A: AAI mode at 30 bpm</B></FONT><FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif">
</FONT></FONT>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><B>Group B: DDD mode at 70 bpm</B></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">Numbered randomisation envelopes
will be given to each centre, specifying the setting for the
implanted pacemaker (Group A: AAI mode at 30 bpm</FONT><FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif">;
</FONT></FONT><FONT FACE="Helvetica, sans-serif">Group B: DDD mode at
70 bpm).</FONT><FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif">
</FONT></FONT>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">These envelopes are to be opened
just prior to implantation, according to the patients’
chronological order of inclusion (envelope n°1 for the 1</FONT><SUP><FONT FACE="Helvetica, sans-serif">st</FONT></SUP><FONT FACE="Helvetica, sans-serif">
implanted patient, envelope n° 2 for the 2</FONT><SUP><FONT FACE="Helvetica, sans-serif">nd</FONT></SUP><FONT FACE="Helvetica, sans-serif">,
and so on).</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><U><B>The randomised order must be
respected so as to preclude any bias in the study.</B></U></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><B>Once implanted, patients have
to call the investigator at the first symptom recurrence. Only
symptoms as severe as spontaneous symptoms are to be considered as
recurrence.</B></FONT><FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif"><B>
</B></FONT></FONT><FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif">
In such case:</FONT></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif">	- </FONT></FONT><FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif"><B>group
A patients</B></FONT></FONT><FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif">,
initially programmed at  30 bpm AAI mode, will be reprogrammed at 70
bpm DDD mode, and are not to be subsequently reset for 30 bpm AAI
mode. </FONT></FONT>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif">	- </FONT></FONT><FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif"><B>group
B patients </B></FONT></FONT><FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif">may
be reprogrammed in an upgraded mode (DDDR ), if available on the
model of implanted PM), with or without increase in heart rate and/or
associated medical treatment. At all events, they are not to be
programmed at a rate inferior to 70 bpm without being removed from
the study</FONT></FONT><FONT FACE="Helvetica, sans-serif">.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">So far as possible, throughout the
duration of the study, the patients are not to be informed as to
their PM programming.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="fr-FR" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><FONT SIZE=3><B><SPAN LANG="en-GB">Spontaneous
symptom recurrence being the index parameter to be assessed, the
study objective is then met and the patient is discharged from the
study.</SPAN><SPAN LANG="en-GB"> </SPAN></B></FONT></FONT>
</P>
<P LANG="en-GB" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><B>5.1.3. FOLLOW-UP IN OUTPATIENT
CLINICS</B></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">Patients are to be followed up as
follows:</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">	- Those </FONT><FONT FACE="Helvetica, sans-serif"><I>presenting
recurrence</I></FONT><FONT FACE="Helvetica, sans-serif"> of the
original symptom are, like any implanted patient, to be followed up
at 2 months and every 6 months in outpatients clinics, out of the
present protocol.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; text-indent: 0.49in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">- Implanted patients </FONT><FONT FACE="Helvetica, sans-serif"><I>not
presenting recurrence</I></FONT><FONT FACE="Helvetica, sans-serif">
of the original symptom are to be followed up at 2 mpnths and every 6
months in outpatients clinics, as part of the present study (per
protocol), for 24 months, each visit comprising:</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">- a physical examination for
adverse events;</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">- pacemaker control;</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">- report of patient’s symptoms
(clinical questionnaire and review of patients self-report diary) so
as to confirm or not any symptom recurrence. In case of confirmed
recurrence, the PM is to be reprogrammed acording to § 5.1.2 and the
study is to be considered as terminated as of this date. </FONT>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">So, to avoid any unnecessary delay
between symptoms recurrence and control, an effort is suggested to
inform the patient’s GP to respect the protocol and to reduce the
time for the investigator visit. </FONT>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="font-style: normal">
<FONT FACE="Helvetica, sans-serif"><B>5.2. END OF STUDY AND THE
VARIOUS DISCHARGE CRITERIA</B></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="font-style: normal">
<FONT FACE="Helvetica, sans-serif"><B>5.2.1. DEFINITION OF END OF
STUDY</B></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">A patient shall be deemed to have
terminated the study when he or she has presented a vagal symptom
recurrence at least as severe as the spontaneous symptoms and leading
to reprogrmming the pacemaker according to § 5.1.2, or when, not
having presented any such recurrence, he or she has completed 24
months’ follow-up.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal; page-break-before: always">
<FONT FACE="Helvetica, sans-serif"><B>5.2.2. CONDITIONS FOR PREMATURE
DISCHARGE</B></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">A patient may leave prematurely
the study for one of the following reasons: </FONT>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">- consent withdrawn during study
period *</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">- lost to follow-up</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">- serious adverse event</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">- PM explantation</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">- investigator decision.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in">
<FONT FACE="Helvetica, sans-serif"><I>* certified and signed by the
patient on the initial consent form</I></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif">The reason
for withdrawal has to be noted at the end of the case report form
(CRF ) and the data obtained for such patients up to their withdrawal
may be used in the statistical analysis </FONT></FONT><FONT FACE="Helvetica, sans-serif">
as “intention ot treat”.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><B>5.2.3. PATIENT </B></FONT><FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif"><B>LOST
TO FOLLOW-UP</B></FONT></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif">A patient is
considered lost to follow-up when he or she fails to attend two FU
consultations despite at least two written and/or telephone reminders
for each control visit. Data gathered are in that case to be used in
the Per Protocol analysis up to the date at which follow-up ceased</FONT></FONT><FONT FACE="Helvetica, sans-serif">.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><B>5.2.4. NON-INCLUSION CRITERION
DISCOVERED DURING STUDY PERIOD</B></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">The discovery of a non-inclusion
criterion in a patient who has been included and implanted will not
necessarily entail their removal from the study. The decision may be
discussed with the principal investigator. If the patient is in fact
removed, their data collected up to the time of such removal may
still be used in the Per Protocol analysis.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><B>6 – STATISTICAL
CONSIDERATIONS</B></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">The forecast inclusion rate is of
15 to 20 patients per month. It is estimated that 10% of these will
be ATP positive.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><B>6.1. ANALYSIS GROUPS </B></FONT>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">The main analysis will be of the
Per Protocol type, applying solely to patients who: </FONT>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">	- have been treated as per
protocol, or </FONT>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">	- present only minor protocol
deviations.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">A further analysis in “intention
to treat” will also be made, including all implanted patients.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">-  Protocol deviations</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">	</FONT><FONT FACE="Helvetica, sans-serif"><I>Minor
protocol deviations</I></FONT><FONT FACE="Helvetica, sans-serif"> are
such as do not bias the assessment of the principal study criterion.
An example might be a control visit missed or arrived at late.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">	</FONT><FONT FACE="Helvetica, sans-serif"><I>Major
protocol deviations</I></FONT><FONT FACE="Helvetica, sans-serif"> are
such as do bias the assessment of the principal study criterion
because of a failure to respect all of the inclusion and exclusion
criteria of the study. Patients presenting any such major deviation
will be withdrawn from the Per Protocol analysis.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="font-style: normal">
<FONT FACE="Helvetica, sans-serif">Any protocol deviation has to be
clearly noted down in the CRF, specifying the reasons and type.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="font-style: normal">
<FONT FACE="Helvetica, sans-serif"><B>6.2. STATISTICAL ANALYSIS (T.
Church, Ph.D.)</B></FONT></P>
<P LANG="en-GB" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">The statistical  analysis will be
conducted by the project manager. Descriptive analysis will be made
of all variables recorded in either treatment group. Groups A and B
will be compared by appropriate methods.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">Recurrence rates during each
setting period will be compared for each patient. If necessary, the
sequence of the PM settings will be examined in the whole study
population, to see whether it is a factor influencing recurrence
rates.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><B>6.3. SAMPLE SIZE</B></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><I>Null hypothesis</I></FONT><FONT FACE="Helvetica, sans-serif">:
</FONT>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">The cumulative percentage syncope
recurrence in the 30 bpm AAI-mode stimulated group, </FONT><FONT FACE="Helvetica, sans-serif"><I>r</I></FONT><SUB><FONT FACE="Helvetica, sans-serif"><I>p</I></FONT></SUB><FONT FACE="Helvetica, sans-serif">,
equals that in the 70 bpm DDD-mode group, </FONT><FONT FACE="Helvetica, sans-serif"><I>r</I></FONT><SUB><FONT FACE="Helvetica, sans-serif"><I>w</I></FONT></SUB><FONT FACE="Helvetica, sans-serif">.
Thus, </FONT><FONT FACE="Helvetica, sans-serif"><I>r</I></FONT><SUB><FONT FACE="Helvetica, sans-serif"><I>p</I></FONT></SUB><FONT FACE="Helvetica, sans-serif"><I>=r</I></FONT><SUB><FONT FACE="Helvetica, sans-serif"><I>w</I></FONT></SUB><FONT FACE="Helvetica, sans-serif"><I>=r</I></FONT><SUB><FONT FACE="Helvetica, sans-serif"><I>0</I></FONT></SUB><FONT FACE="Helvetica, sans-serif">.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><I>Alternative hypothesis</I></FONT><FONT FACE="Helvetica, sans-serif">:
</FONT><FONT FACE="Helvetica, sans-serif"><I>r</I></FONT><SUB><FONT FACE="Helvetica, sans-serif"><I>p</I></FONT></SUB><FONT FACE="Helvetica, sans-serif"><I>=ar</I></FONT><SUB><FONT FACE="Helvetica, sans-serif"><I>w</I></FONT></SUB><FONT FACE="Helvetica, sans-serif">,
where </FONT><FONT FACE="Helvetica, sans-serif"><I>a</I></FONT><FONT FACE="Symbol, serif"></FONT><FONT FACE="Helvetica, sans-serif">1.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">The required number of subjects
was calculated using Wu, Fisher and DeMets’ method, with a first
order relative risk of </FONT><FONT FACE="Symbol, serif"></FONT><FONT FACE="Helvetica, sans-serif">,
power 1-</FONT><FONT FACE="Symbol, serif"></FONT><FONT FACE="Helvetica, sans-serif">,
</FONT><FONT FACE="Helvetica, sans-serif"><I>r</I></FONT><SUB><FONT FACE="Helvetica, sans-serif"><I>0</I></FONT></SUB><FONT FACE="Helvetica, sans-serif">
and </FONT><FONT FACE="Helvetica, sans-serif"><I>a</I></FONT><FONT FACE="Helvetica, sans-serif">.
Based on Flammang et al’s (1997) findings, </FONT><FONT FACE="Symbol, serif"></FONT><FONT FACE="Helvetica, sans-serif">=0.05,
</FONT><FONT FACE="Helvetica, sans-serif"><I>r</I></FONT><SUB><FONT FACE="Helvetica, sans-serif"><I>0</I></FONT></SUB><FONT FACE="Helvetica, sans-serif">=0.40,
the values chosen for 1-</FONT><FONT FACE="Symbol, serif"></FONT><FONT FACE="Helvetica, sans-serif">
et 1-</FONT><FONT FACE="Helvetica, sans-serif"><I>a</I></FONT><FONT FACE="Helvetica, sans-serif">
show that n = 200 subjects gives a reasonable 95 % power of
demonstrating a difference in recurrence rates between the two
groups.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<TABLE WIDTH=470 BORDER=0 CELLPADDING=2 CELLSPACING=0>
	<COL WIDTH=45>
	<COL WIDTH=50>
	<COL WIDTH=63>
	<COL WIDTH=72>
	<COL WIDTH=76>
	<COL WIDTH=61>
	<COL WIDTH=75>
	<TR VALIGN=TOP>
		<TD WIDTH=45 HEIGHT=25 BGCOLOR="#ffffff">
			<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
			<BR>
			</P>
		</TD>
		<TD COLSPAN=6 WIDTH=417 BGCOLOR="#ffffff">
			<P LANG="en-GB" CLASS="western" ALIGN=CENTER STYLE="margin-right: -0.2in; font-style: normal">
			<FONT FACE="Helvetica, sans-serif"><B>Power</B></FONT></P>
			<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
			<BR>
			</P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=45 HEIGHT=21 BGCOLOR="#ffffff">
			<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in">
			<BR>
			</P>
		</TD>
		<TD WIDTH=50 BGCOLOR="#ffffff">
			<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
			<BR>
			</P>
		</TD>
		<TD WIDTH=63 BGCOLOR="#ffffff">
			<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
			<FONT FACE="Helvetica, sans-serif"><B>0.75</B></FONT></P>
		</TD>
		<TD WIDTH=72 BGCOLOR="#ffffff">
			<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
			<FONT FACE="Helvetica, sans-serif"><B>0.80</B></FONT></P>
		</TD>
		<TD WIDTH=76 BGCOLOR="#ffffff">
			<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
			<FONT FACE="Helvetica, sans-serif"><B>0.85</B></FONT></P>
		</TD>
		<TD WIDTH=61 BGCOLOR="#ffffff">
			<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
			<FONT FACE="Helvetica, sans-serif"><B>0.90</B></FONT></P>
		</TD>
		<TD WIDTH=75 BGCOLOR="#ffffff">
			<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
			<FONT FACE="Helvetica, sans-serif"><B>0.95</B></FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=45 HEIGHT=21 BGCOLOR="#ffffff">
			<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in">
			<BR>
			</P>
		</TD>
		<TD WIDTH=50 BGCOLOR="#ffffff">
			<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
			<FONT FACE="Helvetica, sans-serif"><B>0.50</B></FONT></P>
		</TD>
		<TD WIDTH=63 BGCOLOR="#ffffff">
			<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
			<FONT FACE="Helvetica, sans-serif">164</FONT></P>
		</TD>
		<TD WIDTH=72 BGCOLOR="#ffffff">
			<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
			<FONT FACE="Helvetica, sans-serif">184</FONT></P>
		</TD>
		<TD WIDTH=76 BGCOLOR="#ffffff">
			<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in">
			<FONT FACE="Helvetica, sans-serif"><I>210</I></FONT></P>
		</TD>
		<TD WIDTH=61 BGCOLOR="#ffffff">
			<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
			<FONT FACE="Helvetica, sans-serif">246</FONT></P>
		</TD>
		<TD WIDTH=75 BGCOLOR="#ffffff">
			<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
			<FONT FACE="Helvetica, sans-serif">304</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=45 HEIGHT=21 BGCOLOR="#ffffff">
			<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in">
			<BR>
			</P>
		</TD>
		<TD WIDTH=50 BGCOLOR="#ffffff">
			<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
			<FONT FACE="Helvetica, sans-serif"><B>0.55</B></FONT></P>
		</TD>
		<TD WIDTH=63 BGCOLOR="#ffffff">
			<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
			<FONT FACE="Helvetica, sans-serif">132</FONT></P>
		</TD>
		<TD WIDTH=72 BGCOLOR="#ffffff">
			<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
			<FONT FACE="Helvetica, sans-serif">150</FONT></P>
		</TD>
		<TD WIDTH=76 BGCOLOR="#ffffff">
			<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
			<FONT FACE="Helvetica, sans-serif">170</FONT></P>
		</TD>
		<TD WIDTH=61 BGCOLOR="#ffffff">
			<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in">
			<FONT FACE="Helvetica, sans-serif"><I>198</I></FONT></P>
		</TD>
		<TD WIDTH=75 BGCOLOR="#ffffff">
			<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
			<FONT FACE="Helvetica, sans-serif">244</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=45 HEIGHT=21 BGCOLOR="#ffffff">
			<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in">
			<BR>
			</P>
		</TD>
		<TD WIDTH=50 BGCOLOR="#ffffff">
			<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
			<FONT FACE="Helvetica, sans-serif"><B>0.60</B></FONT></P>
		</TD>
		<TD WIDTH=63 BGCOLOR="#ffffff">
			<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
			<FONT FACE="Helvetica, sans-serif">108</FONT></P>
		</TD>
		<TD WIDTH=72 BGCOLOR="#ffffff">
			<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
			<FONT FACE="Helvetica, sans-serif">122</FONT></P>
		</TD>
		<TD WIDTH=76 BGCOLOR="#ffffff">
			<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
			<FONT FACE="Helvetica, sans-serif">140</FONT></P>
		</TD>
		<TD WIDTH=61 BGCOLOR="#ffffff">
			<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
			<FONT FACE="Helvetica, sans-serif">162</FONT></P>
		</TD>
		<TD WIDTH=75 BGCOLOR="#ffffff">
			<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in">
			<FONT FACE="Helvetica, sans-serif"><I>200</I></FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=45 HEIGHT=21 BGCOLOR="#ffffff">
			<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in">
			<FONT FACE="Helvetica, sans-serif"><I><B>1-a</B></I></FONT></P>
		</TD>
		<TD WIDTH=50 BGCOLOR="#ffffff">
			<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
			<FONT FACE="Helvetica, sans-serif"><B>0.65</B></FONT></P>
		</TD>
		<TD WIDTH=63 BGCOLOR="#ffffff">
			<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
			<FONT FACE="Helvetica, sans-serif">90</FONT></P>
		</TD>
		<TD WIDTH=72 BGCOLOR="#ffffff">
			<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
			<FONT FACE="Helvetica, sans-serif">102</FONT></P>
		</TD>
		<TD WIDTH=76 BGCOLOR="#ffffff">
			<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
			<FONT FACE="Helvetica, sans-serif">116</FONT></P>
		</TD>
		<TD WIDTH=61 BGCOLOR="#ffffff">
			<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
			<FONT FACE="Helvetica, sans-serif">136</FONT></P>
		</TD>
		<TD WIDTH=75 BGCOLOR="#ffffff">
			<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
			<FONT FACE="Helvetica, sans-serif">166</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=45 HEIGHT=21 BGCOLOR="#ffffff">
			<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in">
			<BR>
			</P>
		</TD>
		<TD WIDTH=50 BGCOLOR="#ffffff">
			<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
			<FONT FACE="Helvetica, sans-serif"><B>0.70</B></FONT></P>
		</TD>
		<TD WIDTH=63 BGCOLOR="#ffffff">
			<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
			<FONT FACE="Helvetica, sans-serif">76</FONT></P>
		</TD>
		<TD WIDTH=72 BGCOLOR="#ffffff">
			<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
			<FONT FACE="Helvetica, sans-serif">86</FONT></P>
		</TD>
		<TD WIDTH=76 BGCOLOR="#ffffff">
			<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
			<FONT FACE="Helvetica, sans-serif">98</FONT></P>
		</TD>
		<TD WIDTH=61 BGCOLOR="#ffffff">
			<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
			<FONT FACE="Helvetica, sans-serif">114</FONT></P>
		</TD>
		<TD WIDTH=75 BGCOLOR="#ffffff">
			<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
			<FONT FACE="Helvetica, sans-serif">140</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=45 HEIGHT=21 BGCOLOR="#ffffff">
			<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in">
			<BR>
			</P>
		</TD>
		<TD WIDTH=50 BGCOLOR="#ffffff">
			<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
			<FONT FACE="Helvetica, sans-serif"><B>0.75</B></FONT></P>
		</TD>
		<TD WIDTH=63 BGCOLOR="#ffffff">
			<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
			<FONT FACE="Helvetica, sans-serif">64</FONT></P>
		</TD>
		<TD WIDTH=72 BGCOLOR="#ffffff">
			<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
			<FONT FACE="Helvetica, sans-serif">72</FONT></P>
		</TD>
		<TD WIDTH=76 BGCOLOR="#ffffff">
			<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
			<FONT FACE="Helvetica, sans-serif">82</FONT></P>
		</TD>
		<TD WIDTH=61 BGCOLOR="#ffffff">
			<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
			<FONT FACE="Helvetica, sans-serif">96</FONT></P>
		</TD>
		<TD WIDTH=75 BGCOLOR="#ffffff">
			<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
			<FONT FACE="Helvetica, sans-serif">118</FONT></P>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=7 WIDTH=466 HEIGHT=20 VALIGN=TOP BGCOLOR="#ffffff">
			<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
			<FONT FACE="Helvetica, sans-serif"><B>Sample-size calculation for
			sample of ATP-positive patients randomised between 2 PM
			frequencies.</B></FONT></P>
		</TD>
	</TR>
</TABLE>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="font-style: normal">
<FONT FACE="Helvetica, sans-serif"><B>7 – Study RISK / BENEFIT
analysis</B></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">A preliminary retrospective
single-centre study (4), confirmed by a prospective single-centre
study (5), showed the interest of double-chamber pacemakers in this
kind of vasovagal pathology in which the cardio-inhibitory reflex is
predominant. In both study groups, risk is identical and related to
the PM implantation technique. Experience shows that this kind of
pathology and management rarely jeopardise the patient’s life
expectancy.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">On the other hand, it has been
shown that more than 80% of patients suffering from this kind of
pathology show remission or cessation of symptoms under effective
double-chamber stimulation.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><B>8 – ADVERSE EVENTS AND
ADVERSE TREATMENT EFFECTS - DEFINITION AND NOTIFICATION</B></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><B>8.1. ADVERSE EVENTS</B></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif">An </FONT></FONT><FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif"><B>adverse
event</B></FONT></FONT><FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif">
is any adverse clinical manifestation, </FONT></FONT><FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif"><I>apart
from recurrence of spontaneous vasovagal symptoms, </I></FONT></FONT><FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif">occurring
in a subject, whether or not the event is deemed to be related to the
device or to the procedure. An adverse event may be a sign or a
symptom, several associated symptoms, recurrence or development of an
illness or pre-existing condition or of a new illness, occurring
during the study period. The following such adverse events are
considered </FONT></FONT><FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif"><B>serious</B></FONT></FONT><FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif">:</FONT></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif">	- </FONT></FONT><FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif"><B>death</B></FONT></FONT><FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif">
of patient,</FONT></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif">	-
</FONT></FONT><FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif"><B>hospitalisation</B></FONT></FONT><FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif">
or extension of hospitalisation,</FONT></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif">	- permanent
or potential </FONT></FONT><FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif"><B>disability</B></FONT></FONT><FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif">
or intervention required to prevent such disability, or </FONT></FONT><FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif"><B>organ
damage</B></FONT></FONT><FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif">,</FONT></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif">	-
</FONT></FONT><FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif"><B>life-threatening
risk</B></FONT></FONT><FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif">,</FONT></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif">	- </FONT></FONT><FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif"><B>cancer</B></FONT></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><B>8.2. ADVERSE TREATMENT EFFECTS</B></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">An </FONT><FONT FACE="Helvetica, sans-serif"><B>adverse
treatment effect</B></FONT><FONT FACE="Helvetica, sans-serif"> is any
dysfunction or alteration in the characteristics or performance of
the study device such as might lead or have lead to a degradation in
the patient’s state or health: e.g., infection of implantation site
or displacement of a stimulation lead.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">All adverse events and/or adverse
treatment events are to be </FONT><FONT FACE="Helvetica, sans-serif"><B>reported
in the CRF</B></FONT><FONT FACE="Helvetica, sans-serif">, whether
reported by the patient or by the investigator. The minimum to be
reported is: type of event, duration (onset, offset), severity,
location, action (treatment) undertaken by investigator, results in
patient, and possible treatment link. The investigator shall follow
up all adverse events and adverse treatment effects throughout the
study period, and note them in the CRF.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">The investigator shall use the
appropriate form in the observations notebook to report, </FONT><FONT FACE="Helvetica, sans-serif"><B>as
soon as he becomes aware of it,</B></FONT><FONT FACE="Helvetica, sans-serif">
any serious adverse event to the study monitor. The minimum to be
reported is: type of event, duration (onset, offset), severity,
location, action undertaken by investigator, results, and possible
link with device, possible link with protocol and medical treatment
administered prior to event. After validation of the data, the
investigator shall </FONT><FONT FACE="Helvetica, sans-serif"><B>fax
</B></FONT><FONT FACE="Helvetica, sans-serif">the form to the
principle investigator </FONT><FONT FACE="Helvetica, sans-serif"><B>within
24 hours.</B></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">In line with French regulations
(</FONT><FONT FACE="Helvetica, sans-serif"><I>Code de la Santé
Publique - Livre II bis - Loi Huriet-Sérusclat </I></FONT><FONT FACE="Helvetica, sans-serif">and
</FONT><FONT FACE="Helvetica, sans-serif"><I>livre V bis -
Dispositions relatives aux dispositifs médicaux</I></FONT><FONT FACE="Helvetica, sans-serif">),
the project manager and the principle investigator are to inform the
competent authority (i.e., the CCPPRB) and the other investigators of
any serious device-linked adverse event.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><B>9 – CONDUCT OF STUDY </B></FONT>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><B>9.1. CASE REPORT FORMS (CRF)</B></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">Paper CRF shall be used and the
data transmitted to the Principal Investigator by mail.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><B>9.2. MONITORING PROCEDURES</B></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">The appended forms (informed
consent, and inclusion/exclusion criteria, etc.) shall be checked by
the project manager via the network of technical sales engineers. </FONT>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">The investigator has to keep all
the source documents at the project manager’s and the principle
investigator’s disposal, including the informed consent form, the
surgical report, the follow-up reports, and so on. The monitor shall
respect the confidentiality of all of this information.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">The investigator has the
responsibility of filling in the CRF in due time and sending them to
the principle investigator on request. On reception, each CRF has to
be archived for 10 years by each investigator. </FONT>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><B>9.3. QUALITY ASSURANCE </B></FONT>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">The study may be audited at any
time by the regulatory authorities or by the project manager, to
evaluate the Good Clinical Practices, the EN 540 standard and the
respect of the protocol. Any change to the protocol is to be agreed
by the project project manager and by the principal investigator.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">The principle investigator
undertakes to submit any amendment to the CCPPRB of Poitou-Charentes
(France).</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><B>9.4. STUDY REPORT AND
PUBLICATION OF RESULTS</B></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">The property of the data collected
in this study shall shared between the sponsor and the investigators.
The data analysis and the statistical report will be prepared by D.
Flammang, M.D., the principal investigator, who shall also present
and publish the clinical report of the study in association with the
other investigators.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><B>9.5. ADMINISTRATION OF STUDY
MATERIAL</B></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">The pacemaker and the Striadyne®
needed for the ATP test will be provided by the respective hospitals.
 The pacemekers to be implanted must be CE-labelled commercial
dual-chamber models</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><B>10 – REGULATORY
CONSIDERATIONS</B></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><B>10.1. HELSINKI DECLARATION</B></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">The study is to be conducted in
agreement with the recommendations to physicians performing
biomedical research on human subjects adopted by the 18</FONT><SUP><FONT FACE="Helvetica, sans-serif">th</FONT></SUP><FONT FACE="Helvetica, sans-serif">
World Medical Assembly, Helsinki, Finland, in June 1964 and
subsequent revisions thereto.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="font-style: normal">
<FONT FACE="Helvetica, sans-serif"><B>10.2. ETHICAL COMMITTEE -
C.C.P.P.R.B.</B></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif">The
principal investigator shall secure the ethical committee (CCPPRB )
approval and report any device-linked adverse effects. The informed
consent form and the information letter are to be approved by the
CCPPRB prior to any inclusion. The curriculum vitae of all of the
investigators, along with their Medical Council registration numbers
are to be sent to the CCPPRB on submission</FONT></FONT><FONT FACE="Helvetica, sans-serif">.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><B>10.3. PATIENT’S INFORMED
CONSENT AND INFORMATION </B></FONT>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><U>Before inclusion in the study</U></FONT><FONT FACE="Helvetica, sans-serif">,
the patient shall be given all verbal and written information by each
investigator regarding the study’s aims and procedures and the
risks involved therein. All patients taking part in the study must
</FONT><FONT FACE="Helvetica, sans-serif"><U>sign the informed
consent form</U></FONT><FONT FACE="Helvetica, sans-serif"> prior to
their inclusion. The investigator shall keep the original and a copy
has to be given to the patient. Appendix A presents an example of the
patients’ letter of information and informed consent form.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><B>10.4. INVESTIGATOR’S
RESPONSIBILITIES </B></FONT>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif">The
investigator shall fill in the CRF per follow-up visits and inform
the principal investigator and the project manager within 24 hours of
any serious adverse event or adverse effect related to the device.
The investigator shall ensure that the source data, observations
notebooks and investigator’s file are kept in a safe place
throughout the study. These documents are then to be archived for 10
years</FONT></FONT><FONT FACE="Helvetica, sans-serif">.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">The investigator shall keep
informed the staff involved in the study. He/she shall also ensure
that his/her staff conducting the study are properly qualified.
He/she shall inform the patient’s GP of the patient’s
participation.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><B>10.5. PROTECTION OF PATIENT
DATA</B></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">The study documents are to remain
strictly confidential. In the CRF, the patients will be identified by
a number and their initials. The investigator has to keep an up to
date patient identification list, with the corresponding hospital
form numbers, in the investigator’s file. </FONT>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">The data from the study are to
undergo computerised processing. In line with the French
&quot;Informatique et Liberté&quot; (IT and Liberty) law, they
remain strictly confidential. The patients’ identities shall at no
time be disclosed in any data processing report.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><B>10.6. PROTOCOL DEVIATION</B></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">Should a patient’s medical
condition require a deviation from the protocol, the investigator has
to inform the principal investigator as quickly as possible, and the
latter shall determine whether the patient may remain within the
study. Any protocol deviation has to be clearly reported in the CRF.
Repeated unjustified protocol deviations may result in the closure of
the centre concerned.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal; page-break-before: always">
<FONT FACE="Helvetica, sans-serif"><B>11 - SIGNATURES</B></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif"><B>PROTOCOL
TITLE:</B></FONT></FONT><FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif">
Comparative study of two types of pacing for the treatment of
unexplained syncope (vasovagal syndrome) </FONT></FONT>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif"><B>PROTOCOL
VERSION:</B></FONT></FONT><FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif">
1</FONT></FONT><FONT COLOR="#000000"><SUP><FONT FACE="Helvetica, sans-serif">st
</FONT></SUP></FONT><FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif">October
1999</FONT></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">Having read the present protocol,
we understand its requirements and the study performance conditions.
Our signature below confirms our adherence to the terms of the
protocol and our agreement to perform the study in accordance with
the EN 540 standard, Good Clinical Practice and the French Public
Health Code. We understand that any alteration to the present
protocol has to take the form of a written amendment with prior
agreement from the project manager and the co-ordinator, who are to
inform the CCPPRB of Poitou-Charentes thereof. We understand that any
violation of the present protocol may entail early closure of the
centre in question.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">We further undertake that all of
the devices and accessories used in the framework of the present
study shall be used only in accordance with the present protocol. We
undertake to meet the demands of the Medtronic company and of the
Health Authorities regarding the checking of the data collected in
the study, and the auditing or inspection thereof.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">We undertake to inform the project
manager and the principal investigator of any serious adverse event
as of its observation, whether expected or not, and deemed
device-linked or not</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">___________________________		_____/_____/_____</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">Principal Investigator	Date
(dd/mm/yyyy)</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">Dr Daniel Flammang</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">___________________________		_____/_____/_____</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">Dr Jacques Victor	Date
(dd/mm/yyyy)</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">___________________________		_____/_____/_____</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">Pr Jean-Jacques Blanc	Date
(dd/mm/yyyy)</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">___________________________		_____/_____/_____</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">Dr Pierre Graux		</FONT><FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif">Date
(dd/mm/yyyy)</FONT></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">___________________________		_____/_____/_____</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">Pr Jean Luc Rey	Date (dd/mm/yyyy)</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">___________________________		_____/_____/_____</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">Pr Luc De Roy		Date (dd/mm/yyyy)</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">___________________________		_____/_____/_____</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">Dr Roland Carlioz	Date
(dd/mm/yyyy)</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">___________________________		_____/_____/_____</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">Dr Robert Frank	Date (dd/mm/yyyy)</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">___________________________		_____/_____/_____</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">Dr Guilly		Date (dd/mm/yyyy)</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">___________________________		_____/_____/_____</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">Dr Richard Sutton 	</FONT><FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif">Date
(dd/mm/yyyy)</FONT></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">___________________________		_____/_____/_____</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">Pr Rosanne Kenny	Date (dd/mm/yyyy)</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">___________________________		_____/_____/_____</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif">Project
manager	Date (dd/mm/yyyy</FONT></FONT><FONT FACE="Helvetica, sans-serif">)</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">Dr. Cécile Laiter de Monclin,
Medtronic France</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">___________________________		_____/_____/_____</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif">Sponsor		Date
(dd/mm/yyyy</FONT></FONT><FONT FACE="Helvetica, sans-serif">)</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">M. Yves Drapp, Director Medtronic
France</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=CENTER STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=CENTER STYLE="margin-right: -0.2in; font-style: normal; page-break-before: always">
<FONT FACE="Helvetica, sans-serif"><FONT SIZE=3><B>INFORMATION LETTER</B></FONT></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=JUSTIFY STYLE="font-style: normal; line-height: 0.17in">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=JUSTIFY STYLE="text-indent: 0.02in; font-style: normal; line-height: 0.17in">
<FONT FACE="Helvetica, sans-serif"><B>TITLE OF CLINICAL STUDY</B></FONT><B>:</B><FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif">
Comparative study of two types of pacing for the treatment of
unexplained syncope (vasovagal syndrome)</FONT></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=JUSTIFY STYLE="font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=JUSTIFY STYLE="font-style: normal">
<FONT FACE="Helvetica, sans-serif">Lady or Gentleman,</FONT></P>
<P LANG="en-GB" ALIGN=LEFT><BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="font-style: normal">
<FONT FACE="Helvetica, sans-serif">In view of your clinical
examination and of the syncopes you suffer from, your physician
suggests that you take part in a clinical study of syncope management
by means of an implanted pacemaker.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="font-style: normal">
<FONT FACE="Helvetica, sans-serif">This letter is intended to inform
you about the advantages and disadvantages that you may incur by your
participation in this clinical trial. Please read it carefully, and
ask your physician any questions before you make your decision; if
you decide to participate, then sign the consent form below to
indicate that you agree to take part in the study. A copy of this
document will be given to you.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="font-style: normal">
<FONT FACE="Helvetica, sans-serif">You are subject to recurrent
syncope or pre-syncope. The term “syncope” refers to a sudden
loss of consciousness and of hearing, while “pre-syncope” refers
to a fainting or vertigo without actual loss of consciousness. The
various examinations were unable to identify any cardiac,
neurological or metabolic cause. The fact that your cardiac
assessment, including your reaction to the carotid massage, were
normal rules out any known cause reponsible for your symptoms.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="font-style: normal">
<FONT FACE="Helvetica, sans-serif">At this point, according to
standard practice, it is assumed that the reason for the symptoms may
be a hypersensitivity of the heart itself to the vagal system. In
order to offer you an appropriate treatment, your cardiologist
undertook routine tests intended to reproduce the symptoms of syncope
(or pre-syncope). Two such tests were carried out to confirm the
diagnosis:</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="font-style: normal">
<FONT FACE="Helvetica, sans-serif">1 – the head-up tilt test, in
which a change in body position can rproduce the same symptoms, is
one example;</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="font-style: normal">
<FONT FACE="Helvetica, sans-serif">2 – the other test is performed
without changing position, using a drug which is regularly used since
1950: ATP (Adenosine-5'-triphospate), administered intravenously, can
also cause a cardiac pause or a slowing down of your heart rate. </FONT>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="font-style: normal">
<FONT FACE="Helvetica, sans-serif">If this ATP test is positive, your
cardiologist considers that implanting a pacemaker could be helpful,
as this would reduce the number of syncopes or pre-syncopes. If you
agree to take part in this study, a pacemaker will be implanted in
your thoracic region (usually under the right clavicle), under the
skin, by means of a small incision of about 5 or 6 cm, causing no
aesthetic damage. Implantation requires a surgical operation under
local anaesthetic, with a very low risk of infection, rejection or
local haemorrhage.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="font-style: normal">
<FONT FACE="Helvetica, sans-serif">Several different pacemaker
settings are possible, and we want to find out which one best reduces
the number of recurrences of syncope. Two types of setting have been
chosen for the study, and a randomisation procedure (drawing lots)
will decide which one you will have:</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="font-style: normal">
<FONT FACE="Helvetica, sans-serif">-either a dual chamber stimulation
at a rate of 70 beats per minute</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="font-style: normal">
<FONT FACE="Helvetica, sans-serif">-or a single chamber stimulation
at 30 beats per minutes, which in principle does not pace your heart,
but which will be immediately re-set at 70 bpm as soon as a first
attack recurs.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="font-style: normal">
<FONT FACE="Helvetica, sans-serif">Your cardiologist will follow you
for 2 years and will modify the pacemaker programming if necessary.
This programming is done via a programmer which communicated with the
pacemaker through the skin, and requires no surgery.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="font-style: normal">
<FONT FACE="Helvetica, sans-serif">Following implantation, it is
important to avoid strong electromagnetic sources, such as scanners,
diathermy, therapeutic radiation and certain apparatus used during
surgery. You should inform all of your physicians that you are
bearing a pacemaker; mobile phones and household equipment
(microwaves, etc.) do not affect the pacemaker.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="font-style: normal">
<FONT FACE="Helvetica, sans-serif">After implantation, you will be
asked to come to five follow-up visits, at 2, 6, 12, 18 and 24
months). On these occasions, you will be asked whether you have
experienced recurrence of syncope. By taking part in this study, you
will enjoy a frequent and very attentive follow-up. Your physician
will be able to find the optimal programming for your type of
syncope, according to the tests carried out at inclusion. </FONT>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="font-style: normal">
<FONT FACE="Helvetica, sans-serif">Your physician is of course at
your disposal to explain the alternative possibilities, such as
medical treatment of syncope.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="font-style: normal">
<BR>
</P>
<H3 LANG="en-GB" CLASS="western">FURTHER INFORMATION</H3>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="font-style: normal">
<FONT FACE="Helvetica, sans-serif">All of the elements of this study
are confidential, and the cardiologist following you will be bound to
secrecy. Some nominal data concerning you will undergo computerised
processing. According to the French &quot;</FONT><FONT FACE="Helvetica, sans-serif"><I>Informatique
et Liberté</I></FONT><FONT FACE="Helvetica, sans-serif">&quot; (IT
and Liberty) law, these data will remain strictly confidential. Your
identity will at no time be disclosed in any data processing report,
whether to the Ministry of Health or to Dr Flammang, the principal
investigator of the study.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="font-style: normal">
<FONT FACE="Helvetica, sans-serif">According to the provisions of
</FONT><FONT FACE="Helvetica, sans-serif"><I>Livre II bis </I></FONT><FONT FACE="Helvetica, sans-serif">of
the French Public Health Code (</FONT><FONT FACE="Helvetica, sans-serif"><I>Huriet-Sérusclat</I></FONT><FONT FACE="Helvetica, sans-serif">
law), the sponsor has taken out a third party insurance policy (nº
5.323.759) with the CIGNA Insurance Company of Europe (Le Colisée, 8
Rue de l'Arche, 92419 Courbevoie Cedex, France). The Ethical
Committee  (Consultative Committee for the Protection of Persons in
Biomedical Research -  C.C.P.P.R.B.) of Poitou-Charentes (France), in
charge of examining the study, gave its approval for implementation
on 7</FONT><SUP><FONT FACE="Helvetica, sans-serif">th</FONT></SUP><FONT FACE="Helvetica, sans-serif">
October 1999.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="font-style: normal">
<FONT FACE="Helvetica, sans-serif">200 patients with unexplained
syncope will be taking part in the study. Participation is voluntary;
you can refuse to take part or withdraw at any time, for whatever
reason, and without explanation. Your decision will in no way affect
the quality of care you will receive. </FONT>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="font-style: normal">
<FONT FACE="Helvetica, sans-serif">Should your physician consider
that taking part in the study is not in your best interest, he or she
can decide to stop it. The project manager or the Ministry of Health
may also decide to interrupt the study if necessary. Should the study
end before the scheduled date, you will continue to receive medical
care adapted to your condition.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=CENTER STYLE="font-style: normal; page-break-before: always">
<FONT FACE="Helvetica, sans-serif"><FONT SIZE=3><B>INFORMED CONSENT
FORM</B></FONT></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=CENTER STYLE="font-style: normal; line-height: 0.17in">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=JUSTIFY STYLE="font-style: normal; line-height: 0.17in">
<FONT FACE="Helvetica, sans-serif"><U><B>TITLE OF STUDY</B></U></FONT><FONT FACE="Helvetica, sans-serif"><B>:</B></FONT><FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif"><B>
Comparative study of two types of pacing for the treatment of
unexplained syncope (vasovagal syndrome)</B></FONT></FONT></P>
<P LANG="en-GB" ALIGN=LEFT STYLE="font-style: normal; line-height: 0.17in">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="font-style: normal">
<FONT FACE="Helvetica, sans-serif">Surname and first name(s):
……………………………………………………………….</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="font-style: normal">
<FONT FACE="Helvetica, sans-serif">Date of birth: ….../….../……
Telephone: ____________________________</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="font-style: normal">
<FONT FACE="Helvetica, sans-serif">Address:
____________________________________________________________________
___________________________________________________________________________</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="font-style: normal">
<FONT FACE="Helvetica, sans-serif">Dr …………..………………..of……………………………….
[name of institution] has suggested I take part in a study on the
treatment of unexplained syncope by two types of pacemaker setting.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="font-style: normal">
<FONT FACE="Helvetica, sans-serif">He specified that I am free to
accept or to decline; that will in no way affect the care I shall
receive. Should I so wish, I shall be free at any time to withdraw
from the study. I shall in that case inform Dr …………... , who
will offer me, if I so wish, another treatment. I may at any time ask
for further information from Dr …………………………… at
the following telephone number: ……………………………...….</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="font-style: normal">
<FONT FACE="Helvetica, sans-serif">I have received and understood the
information regarding the aims of study, its duration, the methods
used, the benefits, the disadvantages and possible risks. Data
concerning me will remain strictly confidential.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="font-style: normal">
<FONT FACE="Helvetica, sans-serif">I am also aware of the opinion of
the Ethical Committee (Consultative Committee for the Protection of
Persons in Biomedical Research) of Poitou-Charentes (France), which
examined the project and approved it on 7</FONT><SUP><FONT FACE="Helvetica, sans-serif">th</FONT></SUP><FONT FACE="Helvetica, sans-serif">
October 1999.&nbsp;&nbsp;</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="font-style: normal">
<FONT FACE="Helvetica, sans-serif">I AGREE TO TAKE PART IN THE STUDY
UNDER THE CONDITIONS SPECIFIED IN THE ABOVE LETTER OF INFORMATION
WHICH I HAVE READ AND INITIALLED AND WHICH WAS HANDED TO ME
PERSONALLY.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="font-style: normal">
<FONT FACE="Helvetica, sans-serif">I certify that I am not under any
form of legal guardianship. My consent does not discharge the study
organisers from their responsibilities. I retain all of my legal
rights.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="font-style: normal">
<FONT FACE="Helvetica, sans-serif">Signed at……………………………………
          , on ___/___/____</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="font-style: normal">
<FONT FACE="Helvetica, sans-serif">Dr/Pr
______________________	______________________</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="font-style: normal">
<FONT FACE="Helvetica, sans-serif">Signature of
Investigator		Signature of Patient:</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="font-style: normal">
<FONT FACE="Helvetica, sans-serif">or Co-Investigator			(Preceded by
the words “Read and understood”</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="font-style: normal">
 
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="font-style: normal">
<FONT FACE="Helvetica, sans-serif">(a copy of this document will be
given to the patient, who is to keep it)</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=CENTER STYLE="margin-right: -0.2in; font-style: normal; page-break-before: always">
<FONT FACE="Helvetica, sans-serif"><U><B>REFERENCES</B></U></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">1 - Benditt DG: Neurally mediated
syncopal syndromes: pathophysiological concepts and clinical
evaluation. PACE 1997; 20:572-84</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">2 - Kenny RA, Bayliss J, Ingram A,
Sutton R : Head-up tilt: a useful test for investigating unexplained
syncope. Lancet 1986; 1: 1354-58</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">3 - Fitzpatrick A, Theodorakis G,
Vardas P, Sutton R : Methodology of head-up tilt testing in patients
with unexplained syncope. J Am Coll Cardiol 1991; 17:125-30</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">4 - Flammang D, Church T,
Waynberger M, Chassing A, Antiel M : Can adenosine-5’-triphosphate
be used to select treatment in severe vasovagal syndrome? Circulation
1997; 96:1201-8</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">5 - Flammang D, Antiel M, Church
T, Chassing A, Hamani D, Donal E, Waynberger M: Is a pacemaker
indicated for vasovagal patients with severe cardio-inhibitory reflex
as identified by ATP test? A preliminary randomized trial. Europace
1999: 1; 140-145</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">6 – Boulet S : Place du test à
l’ATP dans le diagnostic des syncopes vaso-vagales. Mémoire de DES
soutenu le 09.10.1998 à l’Université d’Angers, UFR des Sciences
Médicales et Pharmacologiques</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">7 - Puech P, Sassine A, Munoz A,
Masse C, Zettelmaier F, Leenhardt a, Yoshimura H : Electrophysiologic
effects of purine: clinical applications. In Cardiac
Electrophysiology and Arrhythmias, Zipes D, Jalife J, ed.  Grune and
Stratton, Orlando, FL 1985, pp 443-50</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="font-style: normal">
<FONT FACE="Helvetica, sans-serif">8 - Flammang D, Erickson M,
McCarville S, Church T, Hamani D, Donal E : Contribution of head-up
tilt testing and ATP testing in assessing the mechanisms of vasovagal
syndrome: preliminary results and potential therapeutic implications.
Circulation 1999; 99:2427-33</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=CENTER STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=CENTER STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><U><B>OTHER REFERENCES ON THE USE
OF ATP I.V. 20 MG IN RHYTHMOLOGY AND FUNDAMENTAL RESEARCH</B></U></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal; line-height: 150%">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">9 - Pelleg A, Belardinelli:
Cardiac electrophysiology and pharmacology of adenosine: basic and
clinical aspects.  Cardiovasc Res 1993; 27:54-61</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">10 - Pelleg A, Hurt CM,
Soler-Baillo JM, Polansky M: Electrophysiological-anatomic correlates
of ATP-triggered vagal reflex in dogs.  Am J Physiol.  1993; 265
(Heart Circ Physiol 34): H681-H690</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">11 - Sharma AD, Rinne E, Klein GJ,
Yee R, Szabo T: Negative chronotropic effects of adenosine
triphosphate on the sinus node are mediated by muscarinic cholinergic
and not purinergic receptors.  J Am Coll Cardiol 1988; 11: 227A</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">12 - </FONT><FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif">Pelleg
A, Hurt CM:  Mechanism of action of ATP on canine pulmonary vagal C
fibre nerve terminals.  J.  Physiol.  1996; 490:265-75</FONT></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">13 - Armour JA, Huang MH, Pelleg
A, Sylvén C:  Responsiveness of in situ canine nodose ganglion
afferent neurons to epicardial mechanical or chemical stimuli. 
Cardiovascular Research 1994; 28:1218-25</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">14 - Hurt CM, Wang L, Xu J,
Sterious W, Pelleg A:  Electrophysiological-anatomic correlates of
ATP-triggered vagal reflex in dogs.  II.  Vagal afferent traffic.  Am
J Physiol 1994; 267:H1093-97</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">15 - Burnstock G: Purinergic
receptors in the heart.  Circulation Research 1980; 46: I-175-82</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">16 - Belardinelli L, Linden J,
Berne RM: The cardiac effects of adenosine.  Progr Cardiovasc
Diseases 1989; 32:73-97</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">17 - Munoz A, Sassine A, Lehujeur
C, Koliopoulos N, Puech P: Mode d’action des substances
purinergiques dérivées de l’adénine sur la conduction
auriculo-ventriculaire.  Etude expérimentale chez le chien.  Arch
Mal Coeur 1985; 78:143-150</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">18 - Lechat P, Tonet JL, Fontaine
G, Frank R, Grosgogeat Y: Etude des effets de l’aminophylline et de
l’atropine sur le bloc nodal induit par l’adenosine triphosphate.
 Thérapie 1984; 39: 609-17</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">19 - Coumel P, Leclercq JF, Attuel
P, Lavallée JP, Flammang D: Autonomic influences in the genesis of
atrial arrhythmias: atrial flutter and fibrillation of vagal origin. 
In: Cardiac arrhythmias: electrophysiology, diagnosis and management.
 Narula OS ed, Williams and Wilkins Pub. 1979, pp 243-55</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">20 - Brignole M, Menozzi C, Alboni
P, Oddone D, Gianfrachi L, Gaggioli G, Lolli G, Paparella N:  The
effect of exogenous adenosine in patients with neurally-mediated
syncope and sick sinus syndrome.  PACE 1994; 17(Pt.II):2211-16</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">21 - Pelleg A, Mitamura H,
Mitsuoka T, Michelson E, Dreifus L:  Effects of adenosine and
adenosine 5’-triphosphate on ventricular escape rhythm in the
canine heart.  J.  A.C.C.  1986; 8:1145-51</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">22 - Motte G, Waynberger M, Lebars
A, Bouvrain Y: L'adénosine triphosphorique dans les tachycardies
paroxystiques.  Intérêt diagnostique et thérapeutique.  Nouv
Presse Med 1972; 1: 3057-61</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">23 - Hughes FC, Jan Y, Bors V,
Baubion N: Etude de l’action chronotrope de l’ATP chez l’homme.
 Coeur et Médecine Interne 1980; 19:227-34</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">24 - Belhassen B, Ilia R, Pelleg A
et al.:  A comparative study of the electrophysiologic effects of
striadyne, adenosine triphosphate and adenosine in the canine heart.
Cardiology 1985; 72:113-22</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<H6 LANG="en-GB" CLASS="western" STYLE="page-break-before: always">APPENDIXES</H6>
<P LANG="en-GB" CLASS="western" ALIGN=CENTER STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><U><B>A. SINO-CAROTID MASSAGE</B></U></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><I>Contra-indications:</I></FONT><FONT FACE="Helvetica, sans-serif">
Carotid murmur, history of ventricular tachycardia, or recent
cardiovascular accident or myocardial infarctus.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><I>Preparation:</I></FONT><FONT FACE="Helvetica, sans-serif">
Cardiac rescue conditions. BP and ECG continuously monitored before
and during the procedure. </FONT>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><I>Procedure:</I></FONT><FONT FACE="Helvetica, sans-serif">
Successive massage of both carotid sinuses </FONT><FONT FACE="Symbol, serif"></FONT><FONT FACE="Helvetica, sans-serif">
6 seconds, patient inclined at 60º.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><I>Assessment:</I></FONT><FONT FACE="Helvetica, sans-serif">
Positive if asystole </FONT><FONT FACE="Symbol, serif"></FONT><FONT FACE="Helvetica, sans-serif">
3 seconds.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><U><B>B. TILT TEST: WESTMINSTER
PROTOCOL (3)</B></U></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><I>Contra-indications:</I></FONT><FONT FACE="Helvetica, sans-serif">
None known.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><I>Preparation:</I></FONT><FONT FACE="Helvetica, sans-serif">
Test performed in quiet room, outside of any period of dominant
orthosympathetic activity; the room is to be equipped for cardiac
resuscitation, at a temperature of 20°C. Patient stays in lying
position on the tilt table for 15 min prior tilting, during which
time a 5% glucose flush into the brachial vein, ECG recording and
continuous BP recording are set up. Patient attached to table by
waist strap and knee strap, with feet on foot-rest. ECG and BP are
recorded every minute.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><I>Procedure:</I></FONT><FONT FACE="Helvetica, sans-serif">
The table is tilted to 60° for 45 min and ECG and BP recorded at
least every minute. The table is returned to horizontal at end of
test or if positive.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><I>Assessment:</I></FONT><FONT FACE="Helvetica, sans-serif">
Test is considered positive if it reproduces spontaneous symptoms or
similar, associated to severe hypotension and/or bradycardia. Severe
hypotension is defined as SBP ≤ 90 mm Hg (or fall in BP of at least
40%). Bradycardia is defined as a rate of &lt;50 bpm.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">For all patients included in the
study, a negative passive tilt test is to be followed by a second
tilt test under isoproterenol up to a maximum dose of 3 </FONT><FONT FACE="Symbol, serif"></FONT><FONT FACE="Helvetica, sans-serif">/mn
or under Trinitrine Spray 0.4 mg.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><U><B>C. ATP TEST</B></U></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><I>Contra-indications:</I></FONT><FONT FACE="Helvetica, sans-serif">
Atrial or ventricular tachyarrythmia, atrial fibrillation, transitory
or permanent second-degree atrio-ventricular blockade, trifascicular
blockage. Coronary insufficiency and asthma are relative
contra-indications. In this study, the ATP test is performed in sinus
rhythm only.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><I>Preparation:</I></FONT><FONT FACE="Helvetica, sans-serif">
same as for the tilt test. Continuous ECG recording at 25 mm/sec. To
avoid any anticipatory sympathetic reaction, patient is not warned of
transitory vagal signs accompanying the ATP effect. </FONT>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><I>Procedure:</I></FONT><FONT FACE="Helvetica, sans-serif">
Injection of 20 mg bolus of ATP (0.3 mg/kg) in 2 seconds, followed by
5% glucose flush.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><I>Assessment:</I></FONT><FONT FACE="Helvetica, sans-serif">
Initial negative chromotropic or dromotropic effect comes on in under
30 sec. ECG response is in 5 phases, concentrating on the analysis of
phase III, when present.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">-  </FONT><FONT FACE="Helvetica, sans-serif"><B>Phase
I: </B></FONT><FONT FACE="Helvetica, sans-serif">gradual slowing of
sinus rhythm.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><B>- Phase II: </B></FONT><FONT FACE="Helvetica, sans-serif">1</FONT><SUP><FONT FACE="Helvetica, sans-serif">st</FONT></SUP><FONT FACE="Helvetica, sans-serif">
or 2</FONT><SUP><FONT FACE="Helvetica, sans-serif">nd</FONT></SUP><FONT FACE="Helvetica, sans-serif">
degree AV blockade.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><B>- Phase III: </B></FONT><FONT FACE="Helvetica, sans-serif">cardiac
pause of variable duration due to complete AV or SA block; this phase
may be absent.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">Complete AV block during cardiac
pause is defined as follows:</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; text-indent: 0.49in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">- number of blocked P waves  ≥ 3</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; text-indent: 0.49in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">- association or not to a
supraventricular or ventricular escape rhythm of ≤ 25 bpm (i.e.,
cycle of ≥ 2.400 msec)</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><B>	</B></FONT><FONT FACE="Helvetica, sans-serif">-
Calculation of total cardiac pause duration may include a brief 2</FONT><SUP><FONT FACE="Helvetica, sans-serif">nd</FONT></SUP><FONT FACE="Helvetica, sans-serif">
degree AVB (Mobitz I or II) sandwiched between 2 complete AV block
episodes.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><B>- Phase IV:</B></FONT><FONT FACE="Helvetica, sans-serif">
return to initial sinus rhythm via transitory 2</FONT><SUP><FONT FACE="Helvetica, sans-serif">nd</FONT></SUP><FONT FACE="Helvetica, sans-serif">
and 1</FONT><SUP><FONT FACE="Helvetica, sans-serif">st</FONT></SUP><FONT FACE="Helvetica, sans-serif">
degree AV block.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><B>- Phase V: </B></FONT><FONT FACE="Helvetica, sans-serif">reflex
sinus tachycardia.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">Clinical response varies from a
simple flush to true dizziness or syncope. At the end of the test,
the patient is asked to describe the functional signs experienced and
compare them to the spontaneous functional signs.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">In all cases, the final result is
based </FONT><FONT FACE="Helvetica, sans-serif"><B>only on the
presence of an ECG phase III</B></FONT><FONT FACE="Helvetica, sans-serif">.</FONT><FONT FACE="Helvetica, sans-serif"><B>
</B></FONT><FONT FACE="Helvetica, sans-serif">Response is abnormal
(positive) when ATP causes a cardiac pause of &gt; 10 seconds and
normal (negative) when ATP causes cardiac pause of </FONT><FONT FACE="Helvetica, sans-serif"><U>&lt;</U></FONT><FONT FACE="Helvetica, sans-serif">
10 seconds or when there is no cardiac pause (simple bradycardia of
any type).</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><I>Recommendations:</I></FONT><FONT FACE="Helvetica, sans-serif">
The patient should be in a quiet environment.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif">In case of technical problem (bad
venous flush, etc), do not conduct more than 3 consecutive tests in
one patient.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal; page-break-before: always">
<FONT FACE="Helvetica, sans-serif"><B>ATP:</B></FONT><FONT FACE="Helvetica, sans-serif">
Adenosine-5'-triphospate.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><B>TT:</B></FONT><FONT FACE="Helvetica, sans-serif">
</FONT><FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif">Tilt
test</FONT></FONT><FONT FACE="Helvetica, sans-serif">. </FONT>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><B>CTR:</B></FONT><FONT FACE="Helvetica, sans-serif">
Cardio-Thoracic Ratio</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><B>SCM:</B></FONT><FONT FACE="Helvetica, sans-serif">
Sino-Carotid Massage.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><B>BP:</B></FONT><FONT FACE="Helvetica, sans-serif">
Blood Pressure.</FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT FACE="Helvetica, sans-serif"><B>Cardiogenic, neuro-cardiogenic
or vasovagal syndrome:</B></FONT><FONT FACE="Helvetica, sans-serif">
</FONT><FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif">Synonyms
for unexplained syncope, excluding carotid sinus hypersensitivity.
According to the symptoms reproduced in the laboratory, a
vasodepressive syndrome (severe hypotension) is distinguished from
the cardio-inhibitory reflex (severe bradycardia or asystolia).</FONT></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif"><B>Programming
30: </B></FONT></FONT><FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif">	Pacing
in AAI mode at 30 bpm</FONT></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif"><B>Programming
70: </B></FONT></FONT><FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif">	Pacing
in DDD mode at 70 bpm</FONT></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif"><B>Group A:
</B></FONT></FONT><FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif">	Group
A patients’ pacemakers will be set with the 30 bpm programming.
They will be reprogrammed to 70 bpm at the first symptom recurrence.
A return to 30 bpm is not allowed in the present study.</FONT></FONT></P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<BR>
</P>
<P LANG="en-GB" CLASS="western" ALIGN=LEFT STYLE="margin-right: -0.2in; font-style: normal">
<FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif"><B>Group B:
</B></FONT></FONT><FONT COLOR="#000000"><FONT FACE="Helvetica, sans-serif">	Group
B patients’ pacemakers will be set with the 70 bpm programming from
the start of the study. Reprogramming to 30 bpm is not allowed in the
present study.</FONT></FONT></P>
</BODY>
</HTML>